Respiratory medicine experts ArtiQ do not charge licensing fees for their software during this crisis

08/05/2020

Leuven MindGate member ArtiQ also wants to help where they can, now that lung function testing labs are restarting their activities. That is why they are not charging licensing fees for their ArtiQ.PFT software till September, for both existing and new customers.

The COVID-19 crisis has been especially demanding for frontline healthcare professionals like pulmonologists. We are entering a phase now where hospitals start up more of their activities and more patients are again being tested in the lung function departments. Not only will the labs progressively start ramping up the traditional patients, but also the COVID-19 survivors require follow-up that includes regular lung function testing.

The coming months will remain challenging with extra hygienic measures, careful patient selection and support on the COVID departments.

At ArtiQ we want to contribute where we can. Our software supports pulmonologists by automating reporting of pulmonary function tests. It automates protocoling and uses AI to help detect lung diseases, which could help to come to a final diagnosis with fewer tests. In this way, we could support the optimal use of the available testing capacity and help pulmonologists spend their time more with patients, less with administrative work.

“We want pulmonologists to spend their time with their patients, not on report writing. This is something we strongly believe in and is even more important today.” said Marko Topalovic, CEO of ArtiQ

"To ensure hospitals can benefit to the fullest, we are not charging any licensing fees for the ArtiQ.PFT software till September", Topalovic added. "Current customers will not be charged for this period or will have their license period extended. We are working with our local partners, such as Acertys, to work out ways to quickly enroll new hospitals who want to make use of the ArtiQ.PFT software in this period."

ArtiQ is a young, dynamic and innovative spin-off company of the University of Leuven (Belgium). The company was founded early 2019 by four committed founders with an extensive history in respiratory medicine, medical devices, and artificial intelligence.

From their multidisciplinary backgrounds and five years of research, the founders identified the value that novel technologies could bring to all parties in the respiratory world: patients, doctors, healthcare systems, and the industry. ArtiQ empowers medical professionals with artificial intelligence to accurately and timely diagnose, treat and follow-up patients with lung diseases.

With their first artificial intelligence-based software, ArtiQ.PFT, they support the interpretation of pulmonary function tests and improve the diagnostic environment for respiratory diseases. The software has been validated elaborately at UZ Leuven, where it is used to create a report for every patient and has been used for over 45 100 patients since the implementation in February 2018.